Riboflavin as an independent and accurate biomarker for adherence in a randomized double-blind and placebo-controlled clinical trial

V. M.S. Ramanujam, Fatima Nayeem, Karl E. Anderson, Yong Fang Kuo, Nai Wei Chen, Hyunsu Ju, Lee Jane W. Lu

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Background: Medication adherence is critical for success of clinical trials. Objective: To assess oral riboflavin is an adherence marker. Methods: Riboflavin was incorporated into active treatment and placebo pills for a clinical trial lasting for 2 years. Results: The accuracy (area under the receiver operating curve) of urinary riboflavin was 0.91 as a binary classifier of adherence, and was similar or better than for two active study ingredients daidzein (0.92) and genistein (0.87) (all p < 0.0001). Decreased adherence over time was similar in the two study groups. Conclusion: Riboflavin is an accurate and useful biomarker for study pill ingestion.

Original languageEnglish (US)
Pages (from-to)508-516
Number of pages9
JournalBiomarkers
Volume22
Issue number6
DOIs
StatePublished - Aug 18 2017

Keywords

  • Biomarker
  • accuracy
  • adherence
  • clinical trial
  • daidzein
  • genistein
  • medication compliance
  • receiver operating curve
  • riboflavin
  • sensitivity
  • specificity

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Fingerprint Dive into the research topics of 'Riboflavin as an independent and accurate biomarker for adherence in a randomized double-blind and placebo-controlled clinical trial'. Together they form a unique fingerprint.

  • Cite this